Compare AdaptHealth Corp (AHCO) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs Morgan Stanley — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while Morgan Stanley trades at $218.03 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 253.8× AdaptHealth Corp's market cap, and Morgan Stanley pays a 1.8% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | MS | |
|---|---|---|
Market Cap | $1.38B | $350.22B |
Sector | Health | Financials |
52-Week High | $13.38 | $227.19 |
52-Week Low | $8.68 | $139.09 |
Enterprise Value | $3.33B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Morgan Stanley (MS) trades at $222.10, up 3.82% today, near its consensus price target of $225.80. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth, reaching $66.0B in 2025. Technical indicators are bullish, with the current price above key support levels. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive given earnings outperformance and analyst consensus, though risks include volatile cash flows and high debt levels. Upside potential exists if the company maintains its growth trajectory and executes on strategic initiatives like the Anthropic IPO. Investors should monitor interest rate sensitivity and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
